Quick Notes: June 4, 2020

  • Due to the COVID-19 pandemic, the in-person ESCRS and Euretina meetings, scheduled to take place in Amsterdam in October, have been cancelled. Instead, the 38th Congress of the ESCRS and the 20th Euretina Congress will be held in a virtual format.
  • Nicox announced the start of a Phase 3 clinical trial, Mont Blanc, evaluating its NCX 470 treatment for lowering IOP in patients with open-angle glaucoma or ocular hypertension. NCX 470 is the company’s novel, second-generation nitric oxide-donating bimatoprost analog. The Mont Blanc trial will randomize more than 600 patients at sites primarily across the United States.

  • Alcon launched its “No Reason to Wait: Success Starts Now” program, which is aimed at helping eye-care professionals better understand the practice and patient benefits to treating meibomian gland dysfunction. The program is intended for practitioners interested in adopting a Systane iLux system and will help identify new ways to service existing patients while adopting strategies to support a practice’s economic recovery.  

  • Quest Diagnostics received emergency use authorization from the FDA for its self-collection COVID-19 test kit. The test kit is designed to be used at home and uses a nasal swab. Quest Diagnostics intends more than a half-million test kits to be available by end of June, with plans to make additional kits available on an ongoing basis. Quest said specimens collected using the kit may be tested with the company's SARS-CoV-2 RT-PCR test that received an emergency authorization in March.

  • Re-Vana Therapeutics Ltd closed $3.25 million in pre-series A financing. The pre-series A round was oversubscribed by more than $1 million and closed in two tranches. The first tranche of $2.08 million was led by ExSight Ventures, with participation from InFocus Capital Partners and existing U.K. investors, including TechStart Ventures, Clarendon Fund Managers and Qubis Ltd.  Visionary Ventures led the second closing round of $1.17 million, with additional investment from existing investors.   
Quick Notes is published weekly. Unless otherwise noted, the information presented is based on press releases. Find earlier editions here. To submit a press release to be considered for publication, click here